Related Experiment Video
Updated: Mar 30, 2026
Automated High-throughput Behavioral Analyses in Zebrafish Larvae
Published on: July 4, 2013
Pharmacological profiling of zebrafish behavior using chemical and genetic classification of sleep-wake modifiers
Yuhei Nishimura1, Shiko Okabe2, Shota Sasagawa2
1Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine Tsu, Japan ; Mie University Medical Zebrafish Research Center Tsu, Japan ; Department of Systems Pharmacology, Mie University Graduate School of Medicine Tsu, Japan ; Department of Omics Medicine, Mie University Industrial Technology Innovation Institute Tsu, Japan ; Department of Bioinformatics, Mie University Life Science Research Center Tsu, Japan.
Abstract:
Sleep-wake states are impaired in various neurological disorders. Impairment of sleep-wake states can be an early condition that exacerbates these disorders. Therefore, treating sleep-wake dysfunction may prevent or slow the development of these diseases. Although many gene products are likely to be involved in the sleep-wake disturbance, hypnotics and psychostimulants clinically used are limited in terms of their mode of action and are not without side effects. Therefore, there is a growing demand for developing new hypnotics and psychostimulants with high efficacy and few side effects. Toward this end, animal models are indispensable for use in genetic and chemical screens to identify sleep-wake modifiers. As a proof-of-concept study, we performed behavioral profiling of zebrafish treated with chemical and genetic sleep-wake modifiers. We were able to demonstrate that behavioral profiling of zebrafish treated with hypnotics or psychostimulants from 9 to 10 days post-fertilization was sufficient to identify drugs with specific modes of action. We were also able to identify behavioral endpoints distinguishing GABA-A modulators and hypocretin (hcrt) receptor antagonists and between sympathomimetic and non-sympathomimetic psychostimulants. This behavioral profiling can serve to identify genes related to sleep-wake disturbance associated with various neuropsychiatric diseases and novel therapeutic compounds for insomnia and excessive daytime sleep with fewer adverse side effects.
Insights
Zebrafish behavioral profiling effectively identifies sleep-modifying drugs and their mechanisms. This approach aids in developing new treatments for sleep disorders and neurological conditions with fewer side effects.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Sleep-wake state disturbances are common in neurological disorders and can worsen disease progression.
- Current treatments for sleep dysfunction have limited mechanisms of action and potential side effects.
- Developing novel, effective sleep medications with improved safety profiles is a significant unmet need.
Purpose of the Study:
- To establish zebrafish behavioral profiling as a method for identifying sleep-wake modifying compounds.
- To demonstrate the utility of this model in distinguishing drug mechanisms of action.
- To explore its potential for discovering novel therapeutic targets for sleep disorders.
Main Methods:
- Behavioral profiling of zebrafish from 9 to 10 days post-fertilization.
- Treatment of zebrafish with known hypnotic and psychostimulant compounds.
- Analysis of behavioral endpoints to differentiate drug classes and mechanisms.
Main Results:
- Zebrafish behavioral profiling successfully identified drugs affecting sleep-wake states.
- Specific behavioral patterns distinguished GABA-A modulators from hypocretin receptor antagonists.
- The model differentiated between sympathomimetic and non-sympathomimetic psychostimulants.
Conclusions:
- Zebrafish behavioral profiling is a viable proof-of-concept for identifying sleep-wake modifiers.
- This method can accelerate the discovery of novel therapeutics for insomnia and excessive daytime sleep.
- It offers a platform for identifying genes involved in sleep disturbances and neuropsychiatric diseases.
